Simon Alan E, Wu Albert W, Lavori Philip W, Sugarman Jeremy
National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, Maryland, USA.
Am J Prev Med. 2007 May;32(5):370-4. doi: 10.1016/j.amepre.2007.01.007.
Ethical aspects of prevention trials, as they differ from therapeutic trials, have not been fully explored. This article aims to define and demonstrate the existence of "preventive misconception" (PM), a misunderstanding in which research participants in prevention trials make an "overestimate in probability or level of personal protection that is afforded by being enrolled in a trial of a preventive intervention."
A rating tool was developed to evaluate PM, using data collected between August 2000 and July 2002 as part of a nationwide study of the quality of informed consent in a trial of a shingles vaccine. During 2005-2006, two pair of raters assessed the responses of 50 participants to questions asked after the participants had given consent to participate in the shingles trial. Two pair of raters evaluated the response for the presence and type of PM. Each pair of raters adjudicated their responses and inter-rater reliability was assessed.
Adjudicated pairs of raters agreed that 32% (CI: 20.7%-45.9%) of participants showed evidence of PM (kappa=0.71, CI: 0.52-0.90); that 12% (CI: 5.2%-24.2%) of participants underestimated the probability of receiving placebo (kappa=0.53, CI: 0.24-0.83); and that 24% (CI: 14.2%-37.6%) overestimated the likely personal effectiveness of the experimental intervention (kappa=0.42, CI: 0.08-0.76).
This study newly describes the concept of preventive misconception and empirically demonstrates its existence in trials of prevention. Study participants may overestimate the protection that they receive by being enrolled in a trial of prevention, which poses ethical challenges for research.
预防试验的伦理问题与治疗试验不同,尚未得到充分探讨。本文旨在定义并证明“预防误解”(PM)的存在,即预防试验中的研究参与者“高估了参与预防性干预试验所带来的个人保护概率或水平”这一误解。
开发了一种评分工具来评估预防误解,使用2000年8月至2002年7月期间收集的数据,作为一项全国性带状疱疹疫苗试验知情同意质量研究的一部分。在2005 - 2006年期间,两对评分者评估了50名参与者在同意参与带状疱疹试验后对问题的回答。两对评分者评估了预防误解的存在情况和类型。每对评分者对他们的回答进行裁决,并评估评分者间的可靠性。
经裁决的评分者对组一致认为,32%(置信区间:20.7% - 45.9%)的参与者表现出预防误解的证据(kappa = 0.71,置信区间:0.52 - 0.90);12%(置信区间:5.2% - 24.2%)的参与者低估了接受安慰剂的概率(kappa = 0.53,置信区间:0.24 - 0.83);24%(置信区间:14.2% - 37.6%)的参与者高估了实验性干预可能的个人有效性(kappa = 0.42,置信区间:0.08 - 0.76)。
本研究首次描述了预防误解的概念,并通过实证证明了其在预防试验中的存在。研究参与者可能高估了参与预防试验所获得的保护,这给研究带来了伦理挑战。